First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial

Shengxiang Ren,Xicheng Wang,Bao-Hui Han,Yueyin Pan,Jun Zhao,Yufeng Cheng,Sheng Hu,Tianshu Liu,Yalun Li,Ying Cheng,Jifeng Feng,Shanyong Yi,Shanzhi Gu,Shegan Gao,Yongzhong Luo,Ying Liu,Caigang Liu,Huijie Duan,Shuni Wang,Xinfeng Yang,Jia Fan,Caicun Zhou

DOI: https://doi.org/10.1136/jitc-2023-007227

IF: 12.469

2024-02-01

Journal for ImmunoTherapy of Cancer

Abstract:Background The combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety of camrelizumab plus famitinib (a receptor tyrosine kinase inhibitor) as a first-line treatment for advanced or metastatic NSCLC patients with a programmed death ligand-1 (PD-L1) tumor proportion score (TPS) of ≥1%, in an open-label, multicenter, phase 2 basket trial. Methods Eligible patients received camrelizumab (200 mg once every 3 weeks via intravenous infusion) plus oral famitinib at an initial dose of 20 mg once daily. The primary endpoint was the objective response rate (ORR), as assessed by the investigator per Response Evaluation Criteria in Solid Tumors V.1.1. Key secondary endpoints included disease control rate (DCR), duration of respons, progression-free survival (PFS), overall survival (OS), 12-month OS rate, and safety profile. Results Of the enrolled 41 patients, 21 (51.2%) had a PD-L1 TPS of 1–49%. As of the cut-off date on June 22, 2022, the combination regimen of camrelizumab and famitinib achieved an ORR of 53.7% (95% CI 37.4% to 69.3%) and a DCR of 92.7% (95% CI 80.1% to 98.5%). The median PFS was 16.6 months (95% CI 8.3 to not reached), and OS data were not yet mature, with an estimated 12-month OS rate of 76.8% (95% CI 60.0% to 87.3%). The most common treatment-related adverse events of grade 3 or higher included hypertension (22.0%), increased alanine aminotransferase (12.2%), decreased neutrophil count (9.8%), proteinuria (7.3%), decrease platelet count (7.3%), and hypokalemia (7.3%). One (2.4%) patient died from grade 5 hemoptysis, which was considered possibly related to the study treatment by the investigator. Conclusion Camrelizumab plus famitinib demonstrated promising antitumor activity in advanced or metastatic NSCLC patients and had an acceptable safety profile. These findings suggest that this combination regimen could be an alternative therapeutic option and warrant further investigation. Trial registration number NCT04346381 .

oncology,immunology

What problem does this paper attempt to address?

This paper aims to explore the efficacy and safety of camrelizumab combined with famitinib as a first - line treatment regimen in patients with advanced or metastatic non - small - cell lung cancer (NSCLC), especially for those patients with a PD - L1 tumor proportion score (TPS) ≥ 1%. The study evaluated the effectiveness and safety of this combination therapy through an open - label, multicenter, phase 2 basket trial. Specifically, the researchers hope to verify the following hypotheses: - The combined use of camrelizumab (an immune checkpoint inhibitor) and famitinib (a receptor tyrosine kinase inhibitor) can synergistically regulate the tumor microenvironment, thereby improving the treatment effect on patients with advanced or metastatic non - small - cell lung cancer. - Whether this combination therapy can provide an effective, chemotherapy - free first - line treatment option, especially in patients with a higher PD - L1 expression level. - Evaluate the safety of this combination therapy, including the types and frequencies of adverse events it causes, to determine its feasibility and tolerability in clinical applications. The primary endpoint of the study is the objective response rate (ORR), and the secondary endpoints include the disease control rate (DCR), duration of response (DoR), progression - free survival (PFS), overall survival (OS) and the 12 - month OS rate, as well as the safety profile. In addition, the study also explored the relationship between efficacy and PD - L1 TPS or other biomarkers.

First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial

43P Camrelizumab plus famitinib as first-line treatment in advanced NSCLC patients with PD-L1 TPS ≥1%: A report from a multicenter, open-label, phase II basket trial

1439P Brain Radiotherapy Combined with Camrelizumab and Platinum-Based Chemotherapy As First-Line Treatment for Advanced NSCLC with Brain Metastases: A Multicenter, Open-Label, Single-Arm, Phase II Study

Camrelizumab Plus Carboplatin and Pemetrexed As First-Line Therapy for Advanced Non-Squamous Non-Small-cell Lung Cancer: 5-Year Outcomes of the CameL Randomized Phase 3 Study

Camrelizumab Plus Apatinib in Treatment-Naive Patients with Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial

Camrelizumab in Different PD-L1 Expression Cohorts of Pre-Treated Advanced or Metastatic Non-Small Cell Lung Cancer: a Phase II Study.

Effectiveness and Safety of Camrelizumab in Inoperable or Advanced Non-Small Cell Lung Cancer Patients: a Multicenter Real-World Retrospective Observational Study (CTONG2004-ADV).

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A for Nonrandomized, Open-label, Phase II Trial

Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study

Camrelizumab plus famitinib in patients with metastatic colorectal cancer: Results from an open-label, multicenter phase II basket study.

Camrelizumab plus famitinib for advanced renal cell carcinoma or unresectable urothelial carcinoma: Updated results from a phase II trial.

LBA44 Camrelizumab Plus Famitinib Versus Camrelizumab Alone and Investigator’s Choice of Chemotherapy in Women with Recurrent or Metastatic Cervical Cancer

Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer

Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research

Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study

Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study

Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study

Efficacy and safety of camrelizumab combined with chemotherapy (irinotecan combined with platinum) followed by camrelizumab combined with apatinib in the first-line treatment of advanced small cell lung cancer: A phase II study.

Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial

A Phase II Study to Evaluate the Efficacy and Safety of Camrelizumab Plus Famitinib in Advanced or Metastatic Thyroid Cancer.

Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, single-arm, phase 2 study.